BioBlast Pharma (ORPN) Reports Q3 Loss of $0.28/Share

BioBlast Pharma (NASDAQ: ORPN) reported Q3 EPS of ($0.28), versus ($0.25) reported last year.

Cash, cash equivalents and short-term bank deposits as of September 30, 2016, were $12.9 million, compared to $15.7 million as of June 30, 2016, primarily reflecting the Company’s third quarter operating expenditures. The Company expects to have at the end of 2016 between $8 to $9 million in cash, cash equivalents and short-term bank deposits.

For earnings history and earnings-related data on BioBlast Pharma (ORPN) click here.

You May Also Be Interested In

• Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
• Advance Auto Parts falls on revenue miss, weak guidance
• Wolfe remains "broadly bullish on AI semis stocks", names Top Pick